SCHEMBL1968264

SCHEMBL1968264

CCOC(=O)C(NC(C)=O)C(=O)c1cccc(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.51
TAS1R1 Q7RTX1 1/20 0.51
MTNR1A P48039 9/20 0.49
MTNR1B P49286 9/20 0.49
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
ALDH1A1 P00352 2/20 0.47
TSHR P16473 2/20 0.47
MAPK1 P28482 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PARP1 P09874 1/20 0.46
CHRNA1 P02708 1/20 0.44
CHRNG P07510 1/20 0.44
CHRNB1 P11230 1/20 0.44
CHRNB2 P17787 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1398796 0.89 CES2 (0.53) TAS1R3TAS1R1MTNR1AMTNR1BCES2
SCHEMBL1339677 0.83 LMNA (0.48) CES2CES1ALDH1A1TSHRTDP1
SCHEMBL1968423 0.82 CA12 (0.55) MTNR1AMTNR1BALDH1A1NPC1RAB9A
Iodide SCHEMBL5351689 0.81 CA12 (0.54) MTNR1AMTNR1BALDH1A1NPC1RAB9A
Bromide SCHEMBL7614615 0.81 CA12 (0.54) MTNR1AMTNR1BALDH1A1NPC1RAB9A
SCHEMBL1969092 0.80 NPSR1 (0.53) TAS1R3TAS1R1CES2ALDH1A1RAB9A
SCHEMBL18073902 0.80 CES2 (0.54) TAS1R3TAS1R1CES2CES1ALDH1A1
SCHEMBL381114 0.79 ALDH1A1 (0.55) TAS1R3TAS1R1MTNR1AMTNR1BCES2
SCHEMBL2461041 0.79 CES2 (0.53) TAS1R3TAS1R1MTNR1BCES2CES1
SCHEMBL1968428 0.79 CES2 (0.53) TAS1R3TAS1R1MTNR1BCES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-01 US disclosed
EP-2334643-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES Actelion Pharmaceuticals Ltd. (CH) 2011-06-22 EP disclosed
WO-2010044054-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD (CH) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES HCRTR2, HCRTR1, HRH3 TAS1R3 772/4885TAS1R1 1021/4885MTNR1A 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.